Sutro Biopharma, Inc.

University of Ca

Sonia Pollitt

Christopher D Thanos

Ramesh Baliga

Gang Yin

Avinash Gill

Kalyani Penta

Leslie McEvoy

Sunil Bajad

Chris Murray

Alex Steiner

Marc I Diamond

Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use

Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use

Disclosed herein is a high-throughput assay to measure intracellular polyglutamine protein aggregation using fluorescence resonance energy transfer (FRET). Three libraries of over 3000 biologically active small molecules were screened for inhibitory activity, and a lead compound was characterized in detail. Y-27632, an inhibitor of the Rho-associated kinase p160ROCK, diminished polyglutamine protein aggregation at micromolar concentrations, and reduced neurodegeneration in amodel of polyglutamine disease.

Protein aggregation regulators

Growing community of inventors

San Mateo, CA, United States of America

Sonia Pollitt